Kidney impairment may change how MK-8527 works in the body

NCT ID NCT06295796

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how the drug MK-8527 is processed in people with moderate or severe kidney impairment compared to healthy volunteers. Eighteen participants received a single oral dose, and researchers measured drug levels in the blood over time. The goal was to understand how kidney function affects the drug's behavior, not to test any treatment effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MK-8527

What this could lead to

If successful, this study could help doctors determine the right dose of MK-8527 for patients with kidney problems.

What could go wrong

This is a very early, small study (18 participants) focused on drug levels, not on treating any disease. It does not test whether MK-8527 works for any condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research by Design ( Site 0001)

    Chicago, Illinois, 60643, United States